For the purposes of our discussion (phase-3 vs phase-2 results in drug programs), the definition is as follows:
Program-survival bias is the difference between:
a) the aggregate results observed in phase-3 trials actually conducted; and
b) the aggregate results that would have been observed in phase-3 trials if every program were allowed to advance from phase-2 to phase-3 regardless of the observed results in phase-2.